Substance / Medication

Nelfinavir mesylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

AIDS

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Lipid Architectonics for Superior Oral Bioavailability of Nelfinavir Mesylate: Comparative in vitro and in vivo Assessment.

Belubbi Tejashree, Shevade Sukhada, Dhawan Vivek et al. · AAPS PharmSciTech · 2018

PMID: 30209788Observational

Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.

Boffito Marta, Pozniak Anton, Kearney Brian P et al. · Antimicrob Agents Chemother · 2005

PMID: 16189129ObservationalFull text (PMC)

Decrease in methodone levels with nelfinavir mesylate.

McCance-Katz E F, Farber S, Selwyn P A et al. · Am J Psychiatry · 2000

PMID: 10698844Case Report

Development and optimization of solid self-nanoemulsifying drug delivery system (S-SNEDDS) using Scheffe's design for improvement of oral bioavailability of nelfinavir mesylate.

Patel Archita, Shelat Pragna, Lalwani Anita · Drug Deliv Transl Res · 2014

PMID: 25786731Other

The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections.

Musarrat Farhana, Chouljenko Vladimir, Dahal Achyut et al. · J Med Virol · 2020

PMID: 32374457PreclinicalFull text (PMC)

A spray dried Nelfinavir Mesylate particles for enhanced oral bioavailability: Systematic formulation optimization and in-vivo performance.

Kamboj Sunil, Sethi Sheshank, Rana Vikas · Colloids Surf B Biointerfaces · 2019

PMID: 30634155Preclinical

The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.

Sanchez Cecilia G, Molinski Steven V, Gongora Rafael et al. · Arthritis Rheumatol · 2018

PMID: 28940894Preclinical

Quality-by-design based development of a self-microemulsifying drug delivery system to reduce the effect of food on Nelfinavir mesylate.

Kamboj Sunil, Rana Vikas · Int J Pharm · 2016

PMID: 26854426Preclinical

Novel nelfinavir mesylate loaded d-α-tocopheryl polyethylene glycol 1000 succinate micelles for enhanced pediatric anti HIV therapy: In vitro characterization and in vivo evaluation.

Moretton Marcela A, Taira Carlos, Flor Sabrina et al. · Colloids Surf B Biointerfaces · 2014

PMID: 25270729Preclinical

Toxicology and carcinogenesis studies of mixtures of 3'-azido-3'-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos. 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental exposure studies).

[object Object] · Natl Toxicol Program Tech Rep Ser · 2013

PMID: 23385634Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Nelfinavir mesilate (substance)
SNOMED CT: 108707008
UMLS CUI: C0886530

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.